25. 進行性多巣性白質脳症 Progressive multifocal leukoencephalopathy Clinical trials / Disease details


臨床試験数 : 25 薬物数 : 35 - (DrugBank : 21) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 36

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-020369-26-DE
(EUCTR)
29/11/201018/08/2010High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on NatalizumabHigh-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab Immune Reconstitution Inflammatory Syndrome
MedDRA version: 12.1;Level: PT;Classification code 10054014;Term: Immune reconstitution syndrome
Product Name: methylprednisolone
INN or Proposed INN: METHYLPREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Biogen IdecNULLNot RecruitingFemale: yes
Male: yes
20Germany
2NCT01211665
(ClinicalTrials.gov)
September 201029/7/2010Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on NatalizumabImmune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive MultifocalDrug: Methylprednisolone;Drug: PrednisoloneBiogenElan PharmaceuticalsTerminated18 YearsN/AAll3Phase 4United States;Germany